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Abstract 1 
Background & Aims 2 
Bioelectrical impedance vector analysis (BIVA) is a non-invasive method of measuring 3 
human body composition . This offers the potential to evaluate nutritional and hydration 4 
states in cancer. Analysis of BIVA data using z-score (the number of standard deviations 5 
away from the mean value of the reference group) has the potential to facilitate 6 
comparisons between different cancer types. 7 
The aim of this study was to use the BIVA Reactance (R) / Reactance (Xc) z-score method to 8 
evaluate body composition differences in cancer, using data from previously published BIVA 9 
studies. 10 
Methods 11 
Previous studies using BIVA in cancer were identified from the literature. Bioimpedance 12 
measures were analysed using the BIVA RXc z-score graph. The mean vector impedance 13 
measures from the studied populations were transformed into standard deviates (with 14 
respect to the mean and standard deviation of the reference populations). Body 15 
composition was classified according to vector placement (i.e. normal athletic, cachectic, 16 
oedematous and dehydrated). 17 
Results 18 
Seven male and three cancer female populations were evaluated. Body composition was 19 
classified as normal for the majority (n=5), followed by cachexia (n=4) and athletic (n=1) 20 
respectively.  Variation in body composition for the studied populations appeared to be 21 
related to factors, such as gender, disease type and severity.  22 
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Conclusions 23 
The BIVA RXc z-score method has potential to evaluate body composition differences 24 
between cancer groups. This method can study body composition, according to cancer type, 25 
stage, gender and ethnicity. Limitations of the method relate to issues appropriate 26 
reference populations and variability between bioimpedance analysers. Better body 27 
composition assessment has the potential to personalise therapeutic, nutrition and 28 
hydration management. Further work is essential to facilitate in-depth evaluation in these 29 
areas, in order to achieve meaningful use of the BIVA method in clinical practice.    30 
Key words 31 
Bioelectrical impedance vector analysis; Bioelectrical impedance analysis; nutritional 32 
assessment; cancer; body composition; palliative care  33 
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Introduction 34 
People with advanced cancer commonly experience body composition changes (i.e. fat, 35 
bone, water and muscle). [1-4]. Evidence demonstrates that cancer patients with reduced 36 
physical function report poorer quality-of-life[5] and shorter life expectancy compared to 37 
other patients.[6]Bioelectrical impedance analysis (BIA) is a non-invasive method of 38 
measuring human body composition (i.e. analysis of fat, bone, water and muscle).[7] BIA, 39 
delivers a low frequency electrical current and works on the principle that fluid and cellular 40 
structures will provide different levels of resistance to an electrical current as it passes 41 
through a living system.[7] BIA provides the following measurements: Resistance (R - Ohms), 42 
assessing cellular hydration; Reactance (Xc - Ohms), assessing tissue integrity and Phase 43 
Angle (PA - degrees), representing the arc-tangent between R and Xc (PA is a useful 44 
indicator of health and prognosis.[7]). BIA technology has been used to evaluate hydration 45 
and nutrition in several populations.[7, 8]  46 
Bioelectrical impedance vector analysis (BIVA) to assess body 47 
composition in advanced illness 48 
Statistical vector analysis of BIA data enables further analysis of human body composition to 49 
be conducted.[9] Bioelectrical impedance vector analysis (BIVA) uses graphical vectors to 50 
analyse BIA data.[8] Using this method, impedance (Z) is plotted as a vector from its 51 
components R (X axis) and Xc (Y axis), after being standardized by height (H). The RXc graph 52 
represents the sex and race-specific tolerance intervals of a comparative reference 53 
population. Tolerance ellipses are plotted on the RXc graph to represent the 50%, 75% and 54 
95% centiles (i.e. confidence intervals) for the population. (Figure 1 - The RXc graph with 55 
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95%, 75% and 50% tolerance ellipses. Reproduced and modified with permission).[10] The 56 
advantage of this method is that it allows information to be obtained simultaneously about 57 
changes in tissue hydration or soft-tissue mass, independent of regression equations, or 58 
body weight. Therefore, BIVA can be interpreted accurately even if patients are at extremes 59 
of weight or volume distribution. BIVA has been used to study hydration status in a variety 60 
of different diseases[11-19] and to undertake general body composition assessments in lung 61 
cancer[18, 20] and cancers of the head and neck.[21] Our previous research used the BIVA 62 
method to examine associations between hydration status, symptoms and survival in 63 
advanced cancer patients.[22]  64 
BIVA RXc z-score analysis facilitates comparisons between 65 
populations 66 
Statistical conversion of BIVA measurements to z-scores enables researchers to compare 67 
body composition of different study populations.[23] Piccoli et al[23] used this method to 68 
compare BIVA data for a variety of disease groups. To date, no studies have used the BIVA 69 
RXc z-score method to synthesise cancer populations evaluated with BIVA. Consequently, 70 
there is potential to use the BIVA Z score method to evaluate body composition by cancer 71 
type and severity. Such information will potentially help support nutritional assessment and 72 
management in cancer. 73 
Aim 74 
To determine the feasibility of the using the BIVA RXc z-score method to compare body 75 
composition in cancer populations using published bioimpedance data. 76 
 77 
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 6
Materials and Methods 78 
A systematic review reporting BIVA in advanced cancer (published by Nwosu et al 2013[8]) 79 
was used to identify previous studies using BIVA to evaluate body composition in advanced 80 
cancer. Further, an electronic search of the literature using MEDLINE, EMBASE and Pubmed 81 
(combining keywords of “bioelectrical impedance vector analysis" and “Neoplasms[MesH]”, 82 
limited to English language and humans) was conducted to identify relevant studies.  83 
Inclusion criteria for studies 84 
Articles were eligible for review provided that they involved the use of BIA in adult humans 85 
with cancer. The following data was required for the z-score analysis: (i) R/H (Ohm/m) and 86 
Xc/H (Ohm/m) mean for the studied population, (ii) studied population size, (iii) sex-specific 87 
bioimpedance data and (iv) details of the reference population used for the analysis. 88 
Minimum standards for the reference population were as follows: the total sample size 89 
n≥100, the R/H (Ohm/m) mean, R/H (Ohm/m) standard deviation (SD), Xc/H (Ohm/m) mean 90 
and Xc/H (Ohm/m) SD. The Picolli 1995 reference population (Caucasian Europeans, males 91 
(n=354) and females (n=372) aged 18 - 85 years, body mass index (BMI) 16 -31 kg/m
2
, Italy, 92 
analyser = Akern-RJL systems [24]) was used for studies which did not meet the minimum 93 
reference standard. We selected the Piccoli data as it was the most commonly selected 94 
reference population for studies evaluating the BIVA method.  95 
Exclusion criteria for studies 96 
The following articles were excluded: Non English studies; those reporting paediatric 97 
populations; absent data to facilitate the BIVA Z score analysis (see inclusion criteria). 98 
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 99 
BIVA software and z-score analysis 100 
BIVA was conducted using software developed by Professor Antonio Piccoli, University of 101 
Padova.[25]  The mean vector impedance measures for study populations were transformed 102 
into standard deviates with respect to the mean and standard deviation and compared 103 
against their reference population.[24] The z-score is the number of standard deviations 104 
away from the mean value of the reference group.[26] Z-scores can provide information 105 
about an individual measured score, relative to others in the distribution.[27] 106 
Transformation of the BIVA measurements to z-scores facilitates comparison between 107 
different conditions and diseases (Figure 2). Using the RXc z-score graph, individuals within 108 
the 50% tolerance ellipse are considered to have normal body composition, whereas those 109 
in the 75% and 95% tolerance ellipses are abnormal.[25]  110 
Vectors were plotted on the RXc z-score graph to facilitate data comparison. Vectors plotted 111 
within the 50% tolerance ellipse were considered normal. Based on data from the Piccoli 112 
study,[23] the BIVA RXc z-score graph was divided into four quadrants to classify body 113 
composition of populations within the 75% and 95% (i.e. abnormal) tolerance ellipses. These 114 
quadrants were (i) Athletic (high cell mass), top left, (ii) Cachexia (low cell mass), bottom 115 
right; (iii) Oedema, bottom left and (iv) Dehydrated, top right (Figure 2). Body composition 116 
was determined according to the plotted vector position. Further details on the equations 117 
used to calculate the RXc Z score graph analysis are available in the appendix. 118 
Ethical Statement 119 
This study was a secondary analysis of previously published research. Therefore, ethical 120 
approval was not required. 121 
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 8
Results 122 
The literature search returned 15 full text articles using BIVA in people with cancer (Figure 123 
3). Two of these articles were rejected as they are not specific to patients with advanced 124 
cancer. Two studies (Lundberg et al[28] and Gnagnarella et al[29]) were excluded as 125 
insufficient data was available to enable the RXc z-score analysis to be conducted. Of the 126 
remaining eleven studies, some presented the same BIVA data. These included two different 127 
studies, which both reported data for the same breast cancer sample.[30, 31] Similarly, two 128 
studies reported data for the same head and neck cancer sample.[21, 32] We grouped the 129 
relevant studies together to avoid confusion. Consequently, nine of the eleven eligible 130 
studies were included. These nine studies provided data for seven male and three female 131 
populations (Table 1). The studies described different cancer types and stages, which 132 
included advanced cancer of different origin;[22] lung cancer (including a sample of patients 133 
in remission),[18, 20] breast cancer,[30] head and neck cancer[21, 33] and gynaecological 134 
cancer.[34] Details of patient demographics, type of analyser and BIVA z-score analysis are 135 
presented in Table 1. 136 
BIVA RXc z-score analysis 137 
The reference population of Piccoli et al[24] was used as the chosen reference population 138 
for the authors of the Cardoso[34] and Nwosu studies. However, the seven populations 139 
described by Toso et al[18, 20] and Malecka-Massalska[21, 31, 35] [30, 32] used control 140 
groups with sample sizes of n<100 as a reference. We used the Piccoli data[24] as a 141 
reference population for these studies. Consequently, the Piccoli reference population was 142 
used as the reference for all studies in this paper. 143 
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 9
The z-score analysis is presented in Figure 4 and Table 2 (supplementary file). Five 144 
populations were normal (50% tolerance ellipse). These were the male and female cohorts 145 
with various cancers (Nwosu et al 2016[22]), males with lung cancer in remission(Toso el al 146 
2003[18]), males patients with stage III lung cancer (Toso el al 2000 [20]) and females with 147 
gynaecological cancer (Cardoso et al 2017[34]).  Comparatively greater cell mass was noted 148 
in females with the newly diagnosed breast cancer[30] (the vector was superior to the 95% 149 
tolerance ellipse of the athletic quadrant) had. Four groups were cachectic (vectors within 150 
the 75% and 95% tolerance ellipse). This included males with stage IV lung cancer  (Toso et 151 
al 2000[20] - 75% tolerance ellipse), males with local and disseminated lung cancer(Toso et 152 
al 2003[18] - 75% tolerance ellipse), and two populations of males with head and neck 153 
cancer (Malecka-Massalska et al 2013[33]– 75% tolerance ellipse, and Malecka-Massalska et 154 
al 2012, 2014[21, 32] - 95% tolerance ellipse). . 155 
Discussion 156 
Main findings 157 
Seven male and three cancer female populations were evaluated. Body composition was 158 
classified as normal for the majority (n=5), followed by cachexia (n=4) and athletic (n=1) 159 
respectively.  Variation in body composition for the studied populations appeared to be 160 
related to factors, such as gender, disease type and severity.  161 
Strengths and uniqueness of this study 162 
This is first study to use the BIVA z-score method to compare body composition in cancer 163 
populations, using data from previously published bioimpedance data. BIVA offers 164 
advantages over traditional methods of body composition assessment, due to its non-165 
invasive nature and simplicity. BIVA has methodological advantage over traditional BIA 166 
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 10
calculations due to its independence of regression equations (which lack accuracy in 167 
cancer[7]). Furthermore, BIVA can facilitate longitudinal assessments to evaluate body 168 
compositionchanges over time. These properties are useful to evaluate nutrition and 169 
hydration in people affected by cancer, who are unable to tolerate more invasive methods 170 
of assessment. This research demonstrates the potential to use published BIVA data for 171 
larger analysis.  172 
Comparison with previous work 173 
The only previous study to use BIVA RXc z-scores in cancer was the Piccoli et al 2002.[23] 174 
Piccoli plotted data from the vector point for males with stage IV lung cancer (Toso et al 175 
2000[20]) within the cachexia quadrant (75% tolerance ellipse). Our data builds on Piccoli’s 176 
study and describes how, in addition to Toso’s stage IV lung cancer data, three other 177 
populations were also classified as cachectic. This included a lung cancer sample with local 178 
and disseminated disease,[18] and two head and neck cancer cohorts[21, 32, 33]). The 179 
vectors for the advanced cancer population described by Nwosu et al[22] (although plotted 180 
within the normal 50% ellipse) were in a similar position to the lung cancer studies by Toso 181 
et al, [18, 20]. This suggests similarity between these groups (i.e. low muscle mass, with risk 182 
of cachexia), even though body composition was classified as normal. Therefore, 183 
interpretation of BIVA Rxc z-score data requires consideration of clinical factors in addition 184 
to BIVA. 185 
 Previous work illustrates how patients with cancer are prone to develop cachexia as their 186 
condition progresses.[1, 36] However, data about the stage of cancer was only available for 187 
two populations. It is possible that stratification of data by cancer stage may have 188 
demonstrated that individuals with more severe cancer were more likely to be cachexic. 189 
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Furthermore, assessments at different points in the disease trajectory may demonstrate 190 
changing body composition over time. 191 
Our data demonstrates that body composition appeared to be related to cancer type, 192 
disease severity and gender.[37] For example, females with breast[30] and gynaecological 193 
cancers[34] had increased cell mass compared to other populations (demonstrated by more 194 
superior vector placement). Two factors may explain this difference. Firstly, individuals with 195 
breast and gynaecological cancer were comparatively younger than other groups (the mean 196 
age for the breast and gynaecological cancer groups were 53 and 60 years respectively, 197 
whereas most other populations were aged >60 years). Secondly, these patients were 198 
recruited at diagnosis, whereas participants in other studies were recruited later in their 199 
illness.  200 
Limitations 201 
A limitation of this study is that nutritional screening tools were not used in all studies, 202 
which makes nutritional based comparisons difficult. The Subjective Global Assessment 203 
(SGA - a simple bedside method of assessing the risk of malnutrition [38]) was used in the 204 
majority studies. Only one study (Cardoso et al[34]) reported body mass index (BMI) data 205 
according to the requirements of the European Society for Clinical Nutrition and 206 
Metabolism (ESPEN) malnutrition criteria.[39] Therefore, our ability to evaluate how BIVA 207 
RXc z-scores relates to nutritional states is limited. 208 
A small number of studies were evaluated in this analysis and the majority of participants 209 
included in the studies were from white, European or North American populations, which 210 
limits our ability to extrapolate the findings. The under-representation of non-white groups 211 
in these studies may be due to various factors, such as language and cultural barriers.[40] 212 
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Further, as this analysis only included English language studies, it is possible that studies 213 
using BIVA in different cultural contexts were excluded.  214 
The lack of BIVA research in females limits the ability to extrapolate results to women. 215 
Females differ physiologically to males (generally more body fat, less body water, shorter 216 
height and reduced muscle mass compared to men[41, 42]). Of the three studies including 217 
women, two studied female specific cancers (breast[30, 31], cervical[34]) and one studied 218 
with a mix of cancer types.[22] Therefore, no studies in the literature provide meaningful 219 
female-specific BIVA data for any cancers, other than those affecting the breast and cervix.  220 
Our findings are limited by a lack of information about the reasons why reference 221 
populations were chosen   Reference populations may not be representative of the studied 222 
population. This is problematic with the Cardoso et al[34] study, which used an 223 
inappropriate reference population (European white adults) for their analysis of a Brazilian 224 
Pardo (mixed race) sample.[34] It is likely this population was chosen due to the lack of 225 
other suitable reference populations. Furthermore, seven populations used small control 226 
groups (n<100) as their reference, which are inappropriate due to their small size. Although 227 
we used the Piccoli population as the reference for these studies, other reference 228 
population may have been more appropriate. This demonstrates the challenges of using the 229 
BIVA Z score method appropriately when there is variability about how reference 230 
populations are selected. 231 
Different bioimpedance analysers were used throughout the studies included in this 232 
analyser. This may result in slight differences in reactance and resistance values which may 233 
alter the BIVA z-score interpretation. Finally, an inherent limitation of the BIVA method is 234 
that it is a qualitative assessment method which does not provide absolute values of body 235 
composition metrics.[8] Therefore, the method is unable to provide quantitative data on 236 
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body composition variables (e.g. fat free mass, and fluid volume). This is why stratification 237 
of BIVA data according to clinical variables is important (e.g. disease stage, type and 238 
ethnicity), in order to determine clinically meaningful outcomes. 239 
Implications to clinical practice and policy 240 
This analysis supports previous data that describes how body composition in cancer is 241 
related to a number of factors (e.g. stage, type of disease).[36, 43, 44] This study 242 
demonstrates the potential to use the BIVA RXc z-score method to undertake comparative, 243 
multi-group, body composition analysis, which could be useful to compare differences in 244 
cancer according to disease stage and type. This has the potential to personalise 245 
therapeutic, nutrition and hydration based interventions according to an individual’s 246 
physiology. Although the BIVA RXc z-score method has potential use in clinical practice, we 247 
are unable to recommend its routine use in clinical practice (in cancer), due to the limited 248 
number of studies using the method and a lack of data to inform clinical interpretation. 249 
Future research possibilities  250 
Further research studies using bioimpendence are needed to evaluate differences in cancer, 251 
according to disease type, stage, ethnicity and gender. In order to improve the clinical 252 
usefulness of BIVA, future bioimpedance studies should report all the relevant data (and 253 
standard deviations) required to conduct BIVA[45] (i.e. age (years), Height (m), BMI (Height 254 
(H)
2
/m), weight(kg), R (Ohm), R/H ( Ohm/m), Xc (Ohm), Xc/H ( Ohm/m), PA  (degrees)). 255 
Researchers should justify the reasons for the choice of reference populations, stating why 256 
the chosen population is best suited for their analysis. Inclusion of this information will 257 
enable researchers to conduct BIVA analyses without needing to contact investigators for 258 
further information. Researchers should aim to develop larger, appropriately powered, 259 
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reference populations, to facilitate stratification (by age, gender, ethnicity and other clinical 260 
factors). As a priority, futures studies should generate data for non-white and female 261 
individuals. 262 
Conclusions 263 
The BIVA RXc z-score method can be used to evaluate body composition in people with 264 
cancer. This method can be used to conduct analysis of body composition according to 265 
different variables such as cancer type, stage, gender and ethnicity. Improved assessment 266 
will lead to better understanding of the physiological and biological processes of advanced 267 
cancer. Consequently, BIVA may help healthcare professionals to personalise therapy in 268 
patients with cancer according to their physiology.  269 
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(resistance/reactance); TBW (total body water), FFM (fat free mass), FM (fat mass), PA 290 
(phase angle - degrees), ESPEN (European Society for Clinical Nutrition and Metabolism), 291 
BMI (Body Mass Index -  height/weight
2
 [kg/m
2
]).292 
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Appendix 474 
Formulas for the calculation of the bio-impedance confidence and 475 
tolerance ellipses  476 
The following section has been adapted (with permission) from Piccoli A , Pastori: BIVA 477 
software.[25] 478 
Geometrical parameters for drawing the RXc Graph and the RXc-479 
score Graph 480 
Confidence and tolerance intervals can be calculated for the bivariate normal 481 
distribution.[46-50] A simple linear correlation analysis can be used for calculation following 482 
appropriate modification of the equations.[9, 23]  483 
Given n pairs of observations x and y, with standard deviation sx and sy, and correlation 484 
coefficient r, for a fixed  probability level, the Snedecor's Fα value is taken with 2 and n-2 485 
degrees of freedom. 486 
RXc Graph 487 
The RXc graph semi-axes (L1 and L2) and the slopes (b1 and b2 = -1/b1), of the axes of the 488 
100(1-α)% confidence and tolerance ellipses (e.g. α= 0.05, 0.25, and 0.50 for the 95th, 75th, 489 
and 50th percentile, respectively) can be calculated using the equations 2a and 3a, 490 
respectively. 491 
RXc-score graph 492 
The parameters of tolerance ellipses of bivariate Z-scores (RXc Zscore graph) can be 493 
calculated accordingly, using equations 1b and 2b.[23] 494 
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Equation 1 a  495 
,  =496 
√.
 − 1 +	 ±  − 1 +  − 4	 − 11 −  	  497 
 498 
Equation 1 b 499 
 ,   = √.	!	∀ −  ± 	#	∀ −  
 500 
Where 501 
K = F/n·(n-2) for confidence ellipses 502 
K = F·(n+1)/n·(n-2) for tolerance ellipses 503 
Equation 2 a 504 
∃, ∃ = %∃,−∃& = ∋( − ∋)/#∋)∋( ± +	∋( − ∋)/	#∋)∋( 
 505 
Equation 2b 506 
∃, ∃ = ± 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 
 23
Figure and Table Legends 507 
Table 1 Details of the studies included in the BIVA RXc z-score analysis  508 
Key Author Characteristics N Mean 
age 
(years) 
Gender BMI 
(kg/m
2
) 
Tolerance Body 
composition 
Analyser 
 Nwosu 
2016[22] 
 
Mixed cancer 
Males (n=42) mean age 70.6 (SD 
11.0), median 71.0) BMI 26.4 
(SD 5.2) predominantly 
Caucasian, advanced cancer 
with different disease types. 
United Kingdom. 
 
42 70.60 Male 26.4 50% Normal Analyzer 
The EFG3 
ElectroFluidGraph 
Vector Impedance 
Analyser (Akern) 
 Nwosu 
2016[22] 
Mixed cancer 
Female (n=48) mean age 71.6 
(SD 13.3), median 74, BMI 24.1 
(4.7) predominantly Caucasian, 
with different disease types. 
United Kingdom. 
 
48 76.10 Female 24.1 50% Normal Analyzer 
The EFG3 
ElectroFluidGraph 
Vector Impedance 
Analyser (Akern) 
 Toso 
2000[20]  
lung cancer stage IIIB 
Males, n=33. Mean age 67 (SD 
5.0), BMI 25 (SD 5.5) Caucasian, 
lung cancer stage IIIB. Italy. 
 
33 67.00 Male 25.0 50% Normal Analyzer 
BIA-101, RJL/Akern 
Systems, Clinton 
Town- ship, MI, USA 
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 Toso 
2000[20]  
lung cancer stage IV 
Males, n=30, mean age 64 (SD 
7.0), BMI 25 (SD 3.1) Caucasian, 
lung cancer stage IV, Italy.  
 
30 64.00 Male 25.0 75% Cachexia Analyzer 
BIA-101, RJL/Akern 
Systems, Clinton 
Town- ship, MI, USA 
△ Malecka-
Massalska 
2012[30] 
2013[31] 
Breast cancer 
Females, n=34, mean age 
=53.88 (SD 10.84) breast cancer 
(n=34) Poland. 
 
61 53.88 Female - 95% Athletic Analyzer 
ImpediMed 
bioimpedance analysis 
SFB7 BioImp v1.55, 
Queensland, Australia. 
 Malecka-
Massalska 
2012[21] 
2014 [32] 
Head and neck cancer 
Males, n=28, mean age 57.1 (SD 
7.3), BMI 22.8 (5.0), Caucasian, 
head and neck cancer.  
 
34 57.10 Male - 95% Cachexia Analyzer 
ImpediMed 
bioimpedance analysis 
SFB7 BioImp v1.55, 
Queensland, Australia. 佐
 Toso 
2003[18]  
Lung cancer 
Males, n=61, mean age =66 (SD 
6), BMI= 25 (SD 4), Caucasian, 
lung cancer, locally advanced 
and disseminated. 
 
56 66.00 Male 25.0 75% Cachexia Analyzer 
BIA-101, RJL/Akern 
Systems, Clinton 
Township, MI, USA 
X Toso 
2003[18] 
Lung cancer in remission 
Males, n=31, mean age= 63 (SD 
10), BMI= 25 (SD 4) Caucasian, 
lung cancer in remission (n=31) 
 
31 63.00 Male 25.0 50% Normal Analyzer 
BIA-101, RJL/Akern 
Systems, Clinton 
Township, MI, USA 
 Melecka- Head and neck cancer 67 67.00 Male 22.9 75% Cachexia Analyzer 
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Massalska  
2013[33] Males, Caucasian n=67, mean 
age = 56.8 (SD 7.9), BMI 22.9 
(SD 4.4), Caucasian, head and 
neck cancer, Poland. 
ImpediMed 
bioimpedance analysis 
SFB7 BioImp v1.55, 
Queensland, Australia. 
 Cardoso 
2017[34] 
Gynaecological cancer 
Female, n=208, mean age= 60 
(range 51-67), BMI = 
underweight (12(6%), normal 
52(25%), overweight 55 (26%), 
obese 89 (43%). White 
n=89(43%), mixed races 
92(42%), Black 26(13%). 
Gynaecological cancer. Brazil 
 
208 60.00 Female - 50% Normal BIA 450 Bioimpedance 
Analyzer, Biodynamics, 
Shoreline, WA, USA 
 509 
RXc z score data analysed with BIVA software using equations included in the appendix. 510 
 511 
Table 2: Bioimpedance Z score data for the included studies  512 
Study details 
R/H 
(Ohm/m) 
Xc/H 
(Ohm/m) 
Reference population data* 
Z(R) 
score 
Z(Xc) 
score N R/H   
(Ohm/m) 
mean 
R/H   
(Ohm/m) 
SD 
Xc/H 
(Ohm/m) 
Mean 
Xc/H 
(Ohm/m) 
SD 
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Males, mixed cancer - Nwosu 2016[22] 306.6 26.1 354 371.9 43.2 30.8 7.2 0.19 -0.65 
Females, mixed cancer - Nwosu 2016[22] 372.2 29.1 372 298.6 49.0 34.4 7.7 0.01 -0.69 
Males, White, Lung cancer stage IIIB, - Toso 2000[20] 302.0 25.0 354 371.9 43.2 30.8 7.2 0.08 -0.81 
Males, White, Lung cancer stage IV, - Toso 2000[20] 314.0 24.0 354 371.9 43.2 30.8 7.2 0.36 -0.94 
Females with breast cancer - Malecka-Massalska 2012[30] 2013[31] 377.54 53.58 372 298.6 49.0 34.4 7.7 0.12 2.49 
Males with head and neck cancer-  Melecka-Massalska  2013[33] 342.54 27.62 354 371.9 43.2 30.8 7.2 1.02 -0.44 
Males with lung cancer locally advanced and disseminated - Toso 2003[18] 317 26.0 354 371.9 43.2 30.8 7.2 0.43 -0.67 
Males with lung cancer in remission - Toso 2003[18] 287 25.0 354 371.9 43.2 30.8 7.2 -0.27 -0.81 
Males with head and neck cancer - Melecka-Massalska  2013[33] 327.01 28.04 354 371.9 43.2 30.8 7.2 0.66 -0.38 
Females (mixed race) gynaecological cancer - Cardoso 2017[34] 349.8 34.4 372 298.6 49.0 34.4 7.7 -0.45 0.00 
*The Piccoli et al 1995[24] reference population data was used for all studies included in this analysis. BIVA software equations are included in 513 
the appendix. 514 
 515 
  516 
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Figure 1: The RXc graph with 95%, 75% and 50% tolerance ellipses. Reproduced and 517 
modified with permission.[51] 518 
 519 
Figure 2: The BIVA z-score graph: data drawn from the literature and plotted on the RXc z-520 
score graph after transformation of the impedance measurements from several disease 521 
groups into bivariate z-scores (with respect to their reference population). Modified with 522 
permission.[23] 523 
Solid and open circles represent male and female, respectively. A forward or backward 524 
displacement of vectors parallel to the major axis of ellipses was associated with 525 
dehydration or fluid overloading, respectively, reaching extremes out of the poles. Single 526 
score vectors are from athletes,[52] obese subjects of class I to III[53] or patients with 527 
chronic renal failure in conservative treatment, nephrotic syndrome (oedema), lung 528 
cancer,[20] acquired immunodeficiency syndrome in stages WR 3 to 5 or WR 6,[54] and 529 
anorexia nervosa.[55] Repeated score vectors are from climbers before and after high 530 
altitude dehydration,[56] Haemodialysis patients, either lean[57] or obese,[53] before and 531 
after fluid removal with a dialysis session, and dehydrated patients with cholera before and 532 
after fluid infusion.[12] Vectors above or below the major axis (meaning upper left or lower 533 
right half of ellipses) were associated with more or less cell mass in soft tissues, respectively, 534 
with extremes along the minor axis. Abbreviations: CRF = chronic renal failure; HD= 535 
haemodialysis; HDo= obese haemodialysis patients; HIV= human immunodeficiency virus 536 
stages 1-6; Ob/1-3= obese subjects of classes I to III; WR= Walter Reed stages 1-6.  537 
Reproduced with permission.[23] 538 
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Figure 3: Overall selection process for clinical studies included in the BIVA Z score analysis 539 
 540 
Figure 4: RXc z-score graph analysis of bioelectrical impedance vector analysis (BIVA) data 541 
from studies of patients with cancer. 542 
Data drawn from the literature and plotted on the RXc-score graph after transformation of 543 
impedance measurements from several disease groups into bivariate Z scores (with respect 544 
to the Piccoli 1995 reference population[24]). Further details of the equations used for the 545 
analysis are available in the appendix.546 
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